TQB3720 / Sino Biopharm - LARVOL DELTA

Zhengda Tianqing has a big explosion! It has won 11 blockbuster products, aggressively attacking the 220 billion market, and 80 Class 1 new drugs are on the way [Google translation] (Sina Corp) - "On November 25, Zhengda Tianqing's Class 1 new drug TQB2102 for injection received implicit approval for clinical trials. The drug, combined with endocrine drugs, is intended to be used for the treatment of HR-positive, HER2-low-expressing recurrent/metastatic breast cancer after CDK4/6 inhibitor resistance....On November 23, the IND applications for two Class 1 new drugs, TQB3720 tablets and TQB3912 tablets, of Zhengda Tianqing were accepted. Among them, TQB3720 tablets is an androgen receptor (AR) inhibitor used to treat prostate cancer; TQB3912 tablets is an AKT inhibitor used to treat breast cancer."

New trial • Breast Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Prostate Cancer • Solid Tumor

Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR/GPX4 axis activated ferroptosis. (PubMed, Front Pharmacol) - " PCa cells and nude mice models were divided into TQB3720, enzalutamide (ENZ), and control groups. TQB3720 promotes ferroptosis in prostate cancer cells by reducing the AR/SP1 transcriptional complex binding to GPX4 promoter. As a result, it is suggested to be a potential drug for clinic prostate cancer treatment."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • GPX4 • MYC

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets (clinicaltrials.gov) - P1; N=120; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor